pirenzepine has been researched along with Obsessive-Compulsive Disorder in 31 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to investigate the effect of adjunctive olanzapine in patients with obsessive-compulsive disorder (OCD) refractory to paroxetine." | 9.10 | Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. ( Cedro, C; D'Amico, G; D'Arrigo, C; Di Rosa, AE; La Torre, D; Muscatello, MR; Pandolfo, G; Spina, E; Zoccali, R, 2003) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "A series of 10 patients with DSM-IV obsessive-compulsive disorder showing significant residual symptoms following an adequate SSRI trial (12 weeks) were given open-label olanzapine augmentation for a minimum of an additional 8 weeks." | 9.09 | Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. ( Epperson, CN; McDougle, CJ; Potenza, MN; Weiss, EL, 1999) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 9.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "This study evaluates the clinical response to olanzapine used in association with selective serotonin reuptake inhibitors (SSRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD)." | 9.09 | Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. ( Francobandiera, G, 2001) |
| "The aim was to describe the short-term (6 months) effects of olanzapine on behavioral and motor clinical manifestations in a group of 11 patients with Huntington disease." | 7.71 | Short-term effects of olanzapine in Huntington disease. ( Brusa, L; Cannella, M; Porcellini, A; Ruggieri, S; Simonelli, M; Squitieri, F, 2001) |
| " The aim of this study was to investigate the efficacy and tolerability of olanzapine addition to fluvoxamine-refractory OCD patients and to assess if a comorbid chronic tic disorder or a concomitant schizotypal personality disorder was associated with response." | 7.70 | Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. ( Bellino, S; Bogetto, F; Vaschetto, P; Ziero, S, 2000) |
| "The aim of the present study was to investigate the effect of adjunctive olanzapine in patients with obsessive-compulsive disorder (OCD) refractory to paroxetine." | 5.10 | Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. ( Cedro, C; D'Amico, G; D'Arrigo, C; Di Rosa, AE; La Torre, D; Muscatello, MR; Pandolfo, G; Spina, E; Zoccali, R, 2003) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "A series of 10 patients with DSM-IV obsessive-compulsive disorder showing significant residual symptoms following an adequate SSRI trial (12 weeks) were given open-label olanzapine augmentation for a minimum of an additional 8 weeks." | 5.09 | Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. ( Epperson, CN; McDougle, CJ; Potenza, MN; Weiss, EL, 1999) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 5.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "This study evaluates the clinical response to olanzapine used in association with selective serotonin reuptake inhibitors (SSRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD)." | 5.09 | Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. ( Francobandiera, G, 2001) |
| "The aim was to describe the short-term (6 months) effects of olanzapine on behavioral and motor clinical manifestations in a group of 11 patients with Huntington disease." | 3.71 | Short-term effects of olanzapine in Huntington disease. ( Brusa, L; Cannella, M; Porcellini, A; Ruggieri, S; Simonelli, M; Squitieri, F, 2001) |
| " We present three cases in which olanzapine caused a significant exacerbation of obsessive-compulsive symptoms in schizophrenia (two cases) and obsessive-compulsive disorder (one case)." | 3.70 | Olanzapine and obsessive-compulsive symptoms. ( Gournellis, R; Lykouras, L; Malliori, M; Rabavilas, A; Zervas, IM, 2000) |
| " The aim of this study was to investigate the efficacy and tolerability of olanzapine addition to fluvoxamine-refractory OCD patients and to assess if a comorbid chronic tic disorder or a concomitant schizotypal personality disorder was associated with response." | 3.70 | Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. ( Bellino, S; Bogetto, F; Vaschetto, P; Ziero, S, 2000) |
| "Olanzapine is a recently introduced atypical neuroleptic agent for which little information is available on its use in children." | 2.69 | Open-label olanzapine treatment in five preadolescent children. ( King, BH; Krishnamoorthy, J, 1998) |
| "Olanzapine is a serotonin-dopamine-receptor antagonist indicated for use in the treatment of schizophrenia and other psychotic disorders." | 2.40 | Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. ( Bever, KA; Perry, PJ, 1998) |
| "In this open case series, the dose-response relationship of atypical antipsychotic augmentation in the treatment of obsessive compulsive disorder (OCD), and the dose-severity relationship in atypical anti psychotic-induced OC symptoms were examined." | 1.31 | Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. ( Lapierre, Y; Ramasubbu, R; Ravindran, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (29.03) | 18.2507 |
| 2000's | 22 (70.97) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahendran, R | 1 |
| Bajaj, V | 1 |
| Comyn, DJ | 1 |
| Crocq, MA | 1 |
| Leclercq, P | 1 |
| Guillon, MS | 1 |
| Bailey, PE | 1 |
| Safranko, I | 1 |
| Poyurovsky, M | 2 |
| Kurs, R | 1 |
| Weizman, A | 2 |
| D'Amico, G | 1 |
| Cedro, C | 1 |
| Muscatello, MR | 1 |
| Pandolfo, G | 1 |
| Di Rosa, AE | 1 |
| Zoccali, R | 1 |
| La Torre, D | 1 |
| D'Arrigo, C | 1 |
| Spina, E | 1 |
| Baker, RW | 1 |
| Ames, D | 1 |
| Umbricht, DS | 1 |
| Chengappa, KN | 1 |
| Schooler, NR | 1 |
| Bever, KA | 1 |
| Perry, PJ | 1 |
| Morrison, D | 1 |
| Clark, D | 1 |
| Goldfarb, E | 1 |
| McCoy, L | 1 |
| al-Mulhim, A | 1 |
| Atwal, S | 1 |
| Coupland, NJ | 1 |
| Krishnamoorthy, J | 1 |
| King, BH | 1 |
| Potenza, MN | 2 |
| Wasylink, S | 1 |
| Longhurst, JG | 1 |
| Epperson, CN | 2 |
| McDougle, CJ | 2 |
| Mottard, JP | 1 |
| de la Sablonnière, JF | 1 |
| Weiss, EL | 1 |
| Marazziti, D | 2 |
| Pallanti, S | 2 |
| Ohaeri, JU | 1 |
| Degner, D | 1 |
| Bleich, S | 1 |
| Kornhuber, J | 1 |
| Rüther, E | 1 |
| Dorfman-Etrog, P | 1 |
| Hermesh, H | 1 |
| Munitz, H | 1 |
| Tollefson, GD | 1 |
| Koran, LM | 2 |
| Ringold, AL | 1 |
| Elliott, MA | 1 |
| Lykouras, L | 1 |
| Zervas, IM | 1 |
| Gournellis, R | 1 |
| Malliori, M | 1 |
| Rabavilas, A | 1 |
| Bogetto, F | 1 |
| Bellino, S | 1 |
| Vaschetto, P | 1 |
| Ziero, S | 1 |
| Ramasubbu, R | 1 |
| Ravindran, A | 1 |
| Lapierre, Y | 1 |
| Squitieri, F | 1 |
| Cannella, M | 1 |
| Porcellini, A | 1 |
| Brusa, L | 1 |
| Simonelli, M | 1 |
| Ruggieri, S | 1 |
| Seger, A | 1 |
| Lamberti, JS | 1 |
| Marusic, A | 1 |
| Farmer, A | 1 |
| Harel, Z | 1 |
| Hallett, J | 1 |
| Riggs, S | 1 |
| Vaz, R | 1 |
| Kiessling, L | 1 |
| Grant, JE | 1 |
| Francobandiera, G | 1 |
| de Haan, L | 2 |
| Beuk, N | 1 |
| Hoogenboom, B | 1 |
| Dingemans, P | 1 |
| Linszen, D | 1 |
| Hollander, E | 1 |
| Bienstock, CA | 1 |
| Rasmussen, SA | 1 |
| Ravizza, L | 1 |
| Benkelfat, C | 1 |
| Saxena, S | 1 |
| Greenberg, BD | 1 |
| Sasson, Y | 1 |
| Zohar, J | 1 |
| Jonkers, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia[NCT04076371] | 1,640 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pirenzepine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine Antagonists; Humans; Obses | 1998 |
Refractory obsessive-compulsive disorder: state-of-the-art treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug | 2002 |
8 trials available for pirenzepine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Adm | 2002 |
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Humans; Male; Middle Aged; Ob | 2003 |
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Obsessive-Compulsive Disorder; O | 1996 |
Open-label olanzapine treatment in five preadolescent children.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzod | 1998 |
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Hu | 1999 |
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Benzodiazepines; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; | 2000 |
Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Dose-Response Relationship, Drug; Drug A | 2001 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
21 other studies available for pirenzepine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Emergence of compulsive symptoms with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Humans; Male; Obsessive-Compulsive Di | 2002 |
Norepinephrine in the treatment of olanzapine overdose.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Benzodiazepines; Drug Overdose; Humans; Male | 2002 |
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.
Topics: Adult; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Olanz | 2003 |
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Drug Therapy, Combination; Humans; Middle | 2003 |
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Humans; Male; Obsessive-Co | 1998 |
Provocation of obsessive-compulsive behaviour and tremor by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Obsessive-Compulsive Disorder; Olanzap | 1998 |
Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 1998 |
Olanzapine-induced obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Comp | 1999 |
Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluvoxamine; Humans | 1999 |
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2000 |
Olanzapine treatment of obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Obsessive-Compulsive Disorder; Olanzapin | 2000 |
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Obsessive-Compulsiv | 2000 |
Olanzapine and obsessive-compulsive symptoms.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Obsessive-Compulsive Disorder; O | 2000 |
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Comorbidity; Drug Therapy, Combinati | 2000 |
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Dopamine Antagonists; Female; Humans; Ma | 2000 |
Short-term effects of olanzapine in Huntington disease.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Femal | 2001 |
Priapism associated with polypharmacy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Fluvoxamine; Humans; Male; | 2001 |
Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Interactions; Fluoxetine; Humans; Male; Middle Aged; Obs | 2000 |
Antibodies against human putamen in adolescents with anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Antibodies; Benzodiazepines; Body Mass Index; Caudate Nucleus; Enzyme- | 2001 |
Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.
Topics: Age of Onset; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Humans; M | 2001 |
Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Female; Humans; Obsessive-Compulsive Disorder; Olanzapine; | 2002 |